Insulet Revenue 2010-2025 | PODD
Insulet annual/quarterly revenue history and growth rate from 2010 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Insulet revenue for the quarter ending March 31, 2025 was $569M, a 28.82% increase year-over-year.
- Insulet revenue for the twelve months ending March 31, 2025 was $2.199B, a 23.49% increase year-over-year.
- Insulet annual revenue for 2024 was $2.072B, a 22.07% increase from 2023.
- Insulet annual revenue for 2023 was $1.697B, a 30.02% increase from 2022.
- Insulet annual revenue for 2022 was $1.305B, a 18.79% increase from 2021.
| Insulet Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $2,072 |
| 2023 | $1,697 |
| 2022 | $1,305 |
| 2021 | $1,099 |
| 2020 | $904 |
| 2019 | $738 |
| 2018 | $564 |
| 2017 | $464 |
| 2016 | $367 |
| 2015 | $264 |
| 2014 | $231 |
| 2013 | $247 |
| 2012 | $211 |
| 2011 | $152 |
| 2010 | $97 |
| 2009 | $66 |
| Insulet Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-03-31 | $569 |
| 2024-12-31 | $598 |
| 2024-09-30 | $544 |
| 2024-06-30 | $489 |
| 2024-03-31 | $442 |
| 2023-12-31 | $510 |
| 2023-09-30 | $433 |
| 2023-06-30 | $397 |
| 2023-03-31 | $358 |
| 2022-12-31 | $370 |
| 2022-09-30 | $341 |
| 2022-06-30 | $299 |
| 2022-03-31 | $295 |
| 2021-12-31 | $308 |
| 2021-09-30 | $276 |
| 2021-06-30 | $263 |
| 2021-03-31 | $252 |
| 2020-12-31 | $246 |
| 2020-09-30 | $234 |
| 2020-06-30 | $226 |
| 2020-03-31 | $198 |
| 2019-12-31 | $209 |
| 2019-09-30 | $192 |
| 2019-06-30 | $177 |
| 2019-03-31 | $160 |
| 2018-12-31 | $165 |
| 2018-09-30 | $151 |
| 2018-06-30 | $124 |
| 2018-03-31 | $124 |
| 2017-12-31 | $131 |
| 2017-09-30 | $122 |
| 2017-06-30 | $110 |
| 2017-03-31 | $102 |
| 2016-12-31 | $104 |
| 2016-09-30 | $95 |
| 2016-06-30 | $87 |
| 2016-03-31 | $81 |
| 2015-12-31 | $84 |
| 2015-09-30 | $71 |
| 2015-06-30 | $61 |
| 2015-03-31 | $48 |
| 2014-12-31 | $15 |
| 2014-09-30 | $75 |
| 2014-06-30 | $72 |
| 2014-03-31 | $69 |
| 2013-12-31 | $69 |
| 2013-09-30 | $61 |
| 2013-06-30 | $60 |
| 2013-03-31 | $57 |
| 2012-12-31 | $58 |
| 2012-09-30 | $55 |
| 2012-06-30 | $51 |
| 2012-03-31 | $48 |
| 2011-12-31 | $47 |
| 2011-09-30 | $45 |
| 2011-06-30 | $32 |
| 2011-03-31 | $28 |
| 2010-12-31 | $28 |
| 2010-09-30 | $25 |
| 2010-06-30 | $23 |
| 2010-03-31 | $21 |
| 2009-12-31 | $20 |
| 2009-09-30 | $19 |
| 2009-06-30 | $15 |
| 2009-03-31 | $12 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $22.619B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $223.673B | 26.90 |
| Boston Scientific (BSX) | United States | $152.309B | 38.13 |
| Stryker (SYK) | United States | $147.454B | 30.83 |
| EssilorLuxottica (ESLOY) | France | $127.910B | 0.00 |
| Medtronic (MDT) | Ireland | $108.054B | 15.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.940B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.883B | 26.67 |
| ResMed (RMD) | United States | $36.216B | 27.20 |
| GE HealthCare Technologies (GEHC) | United States | $33.352B | 15.84 |
| Agilent Technologies (A) | United States | $31.795B | 21.00 |
| Terumo (TRUMY) | Japan | $28.308B | 36.77 |
| Koninklijke Philips (PHG) | Netherlands | $22.446B | 16.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.861B | 12.11 |
| Baxter (BAX) | United States | $15.559B | 11.62 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.250B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.030B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.641B | 22.45 |
| Lantheus Holdings (LNTH) | United States | $5.453B | 13.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.220B | 18.85 |
| Perrigo (PRGO) | Ireland | $3.576B | 9.06 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.449B | 15.02 |
| ICU Medical (ICUI) | United States | $3.346B | 24.67 |
| Envista Holdings (NVST) | United States | $3.039B | 25.25 |
| QuidelOrtho (QDEL) | United States | $2.269B | 15.60 |
| GN Store Nord (GNNDY) | Denmark | $2.150B | 17.81 |
| LeMaitre Vascular (LMAT) | United States | $1.875B | 41.92 |
| AtriCure (ATRC) | United States | $1.597B | 0.00 |
| Neogen (NEOG) | United States | $1.385B | 17.72 |
| AdaptHealth (AHCO) | United States | $1.200B | 12.19 |
| Green Thumb Industries (GTBIF) | United States | $1.173B | 26.38 |
| Kestra Medical Technologies (KMTS) | United States | $1.150B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.047B | 0.00 |
| InMode (INMD) | Israel | $1.013B | 9.28 |
| Phibro Animal Health (PAHC) | United States | $0.946B | 12.10 |
| Evolus (EOLS) | United States | $0.644B | 0.00 |
| CeriBell (CBLL) | United States | $0.595B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.585B | 0.00 |
| Owens & Minor (OMI) | United States | $0.541B | 4.49 |
| Valneva SE (VALN) | France | $0.536B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.504B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.444B | 0.00 |
| Surmodics (SRDX) | United States | $0.399B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.350B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.341B | 0.00 |
| SNDL (SNDL) | Canada | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.307B | 11.29 |
| Sanuwave Health (SNWV) | United States | $0.293B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.283B | 50.40 |
| Sanara MedTech (SMTI) | United States | $0.278B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| Verano Holdings (VRNOF) | United States | $0.261B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.259B | 0.00 |
| ZimVie (ZIMV) | United States | $0.243B | 11.04 |
| Cerus (CERS) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.229B | 0.00 |
| Biote (BTMD) | United States | $0.216B | 6.06 |
| Brainsway (BWAY) | Israel | $0.194B | 51.35 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.186B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.38 |
| Quanterix (QTRX) | United States | $0.166B | 0.00 |
| Organigram Global (OGI) | Canada | $0.163B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.139B | 17.18 |
| Exagen (XGN) | United States | $0.124B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.118B | 0.00 |
| Agape ATP (ATPC) | $0.105B | 0.00 | |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| MacroGenics (MGNX) | United States | $0.098B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.64 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.067B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| United Health Products (UEEC) | United States | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.84 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |